GLP-3 R

GLP-3R is a research-grade injectable compound designed for the exploration of triple incretin agonism, specifically targeting GLP-1, GIP, and glucagon receptors. This advanced formulation is intended for use in metabolic and obesity research, offering insights into weight loss efficacy, energy expenditure, and cardiometabolic health improvements compared to dual-agonist therapies.

Triple Agonist Mechanism

• GLP-3R activates both GLP-1 and GIP receptors, promoting insulin secretion and appetite suppression, while glucagon receptor activation enhances hepatic fat oxidation and thermogenesis. Preclinical studies have shown significant reductions in body fat and liver steatosis.
• Research indicates that GLP-3R improves glycemic control through multi-pathway modulation, helping to preserve beta-cell function and enhance insulin sensitivity in diabetes models.

Weight Management Potential

• In clinical trials, GLP-3R has demonstrated superior body weight reduction, attributed to its synergistic effects on satiety, caloric intake restriction, and increased energy utilization, making it a valuable tool for studying obesity pathophysiology.
• Studies also suggest that GLP-3R aids in the preservation of lean mass during fat loss, along with benefits for visceral adiposity and metabolic flexibility.

Broader Metabolic Benefits

• GLP-3R is associated with improvements in lipid profiles, blood pressure, and inflammatory markers, highlighting its potential role in cardiometabolic disease research.
• Emerging studies are investigating its applications in the resolution of non-alcoholic fatty liver disease (NAFLD) and renal protection through the reduction of ectopic fat deposition.

For research and laboratory use only. Not for human consumption.